• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有门静脉血栓形成的肝癌患者的特征:白蛋白与生存情况。

Characteristics of HCC Patients with Portal Vein Thrombosis: Albumin and Survival.

作者信息

Carr Brian, Donghia Rossella, Yilmaz Sezai

机构信息

Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya, Turkey.

National Institute of Gastroenterology, IRCCS "Saverio de Bellis", Bari, Italy.

出版信息

Oncology. 2024 Dec 9:1-10. doi: 10.1159/000542774.

DOI:10.1159/000542774
PMID:39653023
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12146428/
Abstract

INTRODUCTION

Presence of macroscopic portal vein thrombosis (PVT) in patients with hepatocellular carcinoma (HCC) has been found to be a major poor prognosis characteristic.

AIMS

The aim of the study was to examine patients with PVT for their clinical characteristics and factors related to both PVT and survival.

METHODS

A large HCC database containing 1,094 patients with PVT and 2,513 patients without PVT was examined. Patients had routine baseline serum liver parameters and alpha-fetoprotein (AFP) levels measured, as well as radiological assessment of maximum tumor diameter (MTD), tumor number, presence of macroscopic PVT, plus survival.

RESULTS

The percent of patients with PVT increased with increase in both MTD and serum AFP levels and liver parameter levels were worse in patients with PVT than without it. A logistic regression model showed that the combination of MTD >5 cm plus AFP >100 IU/mL plus albumin <3.5 g/dL had an odds ratio of 10.988 for the presence of PVT. Normal serum albumin levels significantly reduced the hazard ratio for death in a Cox proportional hazard model and were associated with decreased liver failure.

CONCLUSION

Logistic regression showed the significance of MTD, AFP, and albumin in the presence of PVT, and the Cox model highlighted the importance of albumin levels in decreasing death.

摘要

引言

肝细胞癌(HCC)患者中存在肉眼可见的门静脉血栓形成(PVT)已被发现是一个主要的预后不良特征。

目的

本研究的目的是检查患有PVT的患者的临床特征以及与PVT和生存相关的因素。

方法

检查了一个大型HCC数据库,其中包含1094例患有PVT的患者和2513例未患有PVT的患者。对患者进行了常规基线血清肝脏参数和甲胎蛋白(AFP)水平的测量,以及对最大肿瘤直径(MTD)、肿瘤数量、肉眼可见PVT的存在情况以及生存情况的影像学评估。

结果

患有PVT的患者百分比随着MTD和血清AFP水平的升高而增加,并且患有PVT的患者的肝脏参数水平比未患PVT的患者更差。逻辑回归模型显示,MTD>5 cm加上AFP>100 IU/mL加上白蛋白<3.5 g/dL的组合对于存在PVT的比值比为10.988。在Cox比例风险模型中,正常血清白蛋白水平显著降低了死亡风险比,并且与肝衰竭的减少相关。

结论

逻辑回归显示了MTD、AFP和白蛋白在存在PVT时的重要性,并且Cox模型突出了白蛋白水平在降低死亡方面的重要性。

相似文献

1
Characteristics of HCC Patients with Portal Vein Thrombosis: Albumin and Survival.伴有门静脉血栓形成的肝癌患者的特征:白蛋白与生存情况。
Oncology. 2024 Dec 9:1-10. doi: 10.1159/000542774.
2
Small hepatocellular carcinomas and thrombocytopenia.小肝癌和血小板减少症。
Oncology. 2012;83(6):331-8. doi: 10.1159/000341533. Epub 2012 Sep 18.
3
Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis.经动脉化疗栓塞术治疗伴有门静脉癌栓的肝细胞癌:一项系统评价和Meta分析
HPB (Oxford). 2017 Aug;19(8):659-666. doi: 10.1016/j.hpb.2017.04.016. Epub 2017 May 25.
4
Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma.肝癌患者血小板减少与肿瘤大小的关系。
Oncology. 2012;83(6):339-45. doi: 10.1159/000342431. Epub 2012 Sep 18.
5
Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study.肝细胞癌门静脉血栓形成:一项尸检研究中的年龄和性别分布
J Cancer Res Clin Oncol. 1998;124(7):397-400. doi: 10.1007/s004320050189.
6
Macroscopic Portal Vein Thrombosis in HCC Patients.肝癌患者的巨块型门静脉血栓
Can J Gastroenterol Hepatol. 2018 Jun 13;2018:3120185. doi: 10.1155/2018/3120185. eCollection 2018.
7
Analysis of factors influencing tumor volume doubling time in hepatocellular carcinoma and its predictive value for progression-free survival.肝细胞癌肿瘤体积倍增时间的影响因素分析及其对无进展生存期的预测价值
Sci Rep. 2025 Jul 16;15(1):25840. doi: 10.1038/s41598-025-06349-3.
8
Cluster analysis of hepatocellular carcinoma prognosis using preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin levels: a multi-institutional study.利用术前甲胎蛋白和异常凝血酶原水平对肝细胞癌预后进行聚类分析:一项多机构研究
J Gastrointest Surg. 2025 Apr;29(4):101980. doi: 10.1016/j.gassur.2025.101980. Epub 2025 Jan 28.
9
Correlation between virological response and portal vein thrombosis in patients with chronic hepatitis B.慢性乙型肝炎患者病毒学应答与门静脉血栓形成之间的相关性
Sci Rep. 2025 Jul 1;15(1):20856. doi: 10.1038/s41598-025-04316-6.
10
Effect of combining serum alpha-fetoprotein with LI-RADS v2018 on gadoxetate-enhanced MRI in the diagnosis and prognostication of hepatocellular carcinoma.血清甲胎蛋白与LI-RADS v2018联合应用对钆塞酸增强MRI在肝细胞癌诊断和预后评估中的作用
Eur Radiol. 2025 Feb 10. doi: 10.1007/s00330-025-11418-2.

本文引用的文献

1
Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular Targeted Therapies-Development and Validation of the ABPS Score.经动脉化疗栓塞术联合分子靶向治疗的门静脉癌栓患者的预后评估——ABPS 评分的建立和验证。
Acad Radiol. 2024 Oct;31(10):4034-4044. doi: 10.1016/j.acra.2024.02.039. Epub 2024 Mar 20.
2
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.经动脉化疗栓塞术联合仑伐替尼对比经动脉化疗栓塞术联合索拉非尼作为伴门静脉癌栓的肝细胞癌一线治疗的前瞻性随机研究。
Cancer. 2021 Oct 15;127(20):3782-3793. doi: 10.1002/cncr.33677. Epub 2021 Jul 8.
3
Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes.肿瘤多灶性和血清白蛋白水平可识别出具有不同生存结局的肝细胞癌合并门静脉血栓形成的患者群体。
Ann Med Surg (Lond). 2021 Jun 2;66:102458. doi: 10.1016/j.amsu.2021.102458. eCollection 2021 Jun.
4
The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.门静脉癌栓对不同治疗方案治疗的肝细胞癌患者生存的影响:一项队列研究。
PLoS One. 2021 May 7;16(5):e0249426. doi: 10.1371/journal.pone.0249426. eCollection 2021.
5
Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization.影响接受化疗栓塞的肝癌伴门静脉癌栓患者短期和长期生存的因素。
World J Gastroenterol. 2021 Apr 7;27(13):1330-1340. doi: 10.3748/wjg.v27.i13.1330.
6
I irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis.钇[90Y] 玻璃微球内放射支架治疗合并门静脉血栓形成的肝细胞癌: 一项荟萃分析。
Cancer Radiother. 2021 Jun;25(4):340-349. doi: 10.1016/j.canrad.2020.12.003. Epub 2021 Jan 14.
7
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis.伴有大血管肿瘤血栓形成的晚期肝细胞癌患者接受免疫检查点抑制剂治疗的真实世界结局。
Cancer Immunol Immunother. 2021 Jul;70(7):1929-1937. doi: 10.1007/s00262-020-02845-9. Epub 2021 Jan 6.
8
Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis.基于肝功能和门静脉癌栓的晚期肝细胞癌治疗策略
Hepatol Res. 2020 Dec;50(12):1375-1385. doi: 10.1111/hepr.13567. Epub 2020 Sep 26.
9
Portal Vein Thrombosis and Markers of Inflammation in Hepatocellular Carcinoma.门静脉血栓形成与肝细胞癌炎症标志物。
J Gastrointest Cancer. 2020 Dec;51(4):1141-1147. doi: 10.1007/s12029-020-00489-7.
10
Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease.立体定向体部放疗治疗合并慢性肝病的肝细胞癌伴门静脉癌栓的疗效。
Asia Pac J Clin Oncol. 2021 Jun;17(3):209-215. doi: 10.1111/ajco.13361. Epub 2020 Aug 5.